Abstract Type 2 diabetes (T2D), which has currently become a global pandemic, is a
metabolic disease largely characterised by impaired insulin secretion and action. Significant …

Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

Short-chain fatty acids (SCFAs) are the main metabolites produced by bacterial fermentation
of dietary fibre in the gastrointestinal tract. The absorption of SCFAs is mediated by substrate …

Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for
the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis …

Glucagon-like peptide-1 (GLP-1) released from gut enteroendocrine cells controls meal-
related glycemic excursions through augmentation of insulin and inhibition of glucagon …

G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly
due to their substantial involvement in human pathophysiology and their pharmacological …

Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …

OBJECTIVE This trial compared the efficacy and safety of the first oral glucagon-like peptide
1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo in patients with …

Inflammation contributes to many chronic conditions. It is often associated with circulating
pro-inflammatory cytokines and immune cells. GLP-1 levels correlate with disease severity …

Dysregulation of peptide-activated pathways causes a range of diseases, fostering the
discovery and clinical development of peptide drugs. Many endogenous peptides activate G …